FDA Okays First Targeted Drug for Metastatic Bladder Cancer FDA Okays First Targeted Drug for Metastatic Bladder Cancer

Accelerated approval was granted to erdafitinib for treating locally advanced or metastatic bladder cancer with genetic alterations FGFR3 or FGFR2 after progressing on chemotherapy. A companion diagnostic was also approved.FDA Approvals
Source: Medscape Urology Headlines - Category: Urology & Nephrology Tags: Hematology-Oncology News Alert Source Type: news